4-methyl-N-(4-((3-(2-(methylamino)-4-pyrimidinyl)-2-pyridinyl)oxy)-1-naphthalenyl)-1H-benzimidazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-methyl-N-(4-((3-(2-(methylamino)-4-pyrimidinyl)-2-pyridinyl)oxy)-1-naphthalenyl)-1H-benzimidazol-2-amine
• 英文别名: 7-methyl-N-(4-(3-(2-(methylamino)pyrimidin-4-yl)pyridin-2-yloxy)naphthalen-1-yl)-1H-benzo[d]imidazol-2-amine；4-methyl-N-[4-[3-[2-(methylamino)pyrimidin-4-yl]pyridin-2-yl]oxynaphthalen-1-yl]-1H-benzimidazol-2-amine
• 化学式: C₂₈H₂₃N₇O
• 分子量: 473.537
• InChiKey: NMQGVPMNRSWCJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  101
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-氨基-1-萘酚 在 caesium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 4-methyl-N-(4-((3-(2-(methylamino)-4-pyrimidinyl)-2-pyridinyl)oxy)-1-naphthalenyl)-1H-benzimidazol-2-amine
  参考文献：
  名称：

  Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase

  摘要：

  Selective small molecule inhibitors of Tie-2 kinase are important tools for the validation of Tie-2 signaling in pathological angiogenesis. Reported herein is the optimization of a nonselective scaffold into a potent and highly selective inhibitor of Tie-2 kinase.

  DOI：

  10.1016/j.bmcl.2008.11.056

文献信息

• Multi-cyclic compound and method of use
  申请人：Cee J. Victor

  公开号：US20070213325A1

  公开（公告）日：2007-09-13

  The present invention relates to chemical compounds having a general formula I wherein A, B, C 1 , C 2 , D, L 1 , L 2 and R 3-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Tie-2 and Aurora kinase enzymes thereby influencing angiogenesis and the process of cell cycle and cell proliferation, respectively, to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of various protein kinases.

  本发明涉及具有一般公式I的化合物，其中A、B、C1、C2、D、L1、L2和R3-4在此处定义，并且合成中间体，能够调节各种蛋白激酶受体酶，从而影响与这些激酶活动相关的各种疾病状态和状况。例如，这些化合物能够调节Tie-2和Aurora激酶酶，从而影响血管生成以及细胞周期和细胞增殖过程，以治疗癌症和癌症相关疾病。本发明还包括包括这些化合物的药物组合物，以及治疗与各种蛋白激酶活动相关的疾病状态的方法。
• MULTI-CYCLIC COMPOUNDS AND METHOD OF USE
  申请人：Amgen Inc.

  公开号：EP1994030B1

  公开（公告）日：2010-08-25
• US7868177B2
  申请人：——

  公开号：US7868177B2

  公开（公告）日：2011-01-11
• Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinase
  作者：Victor J. Cee、Alan C. Cheng、Karina Romero、Steve Bellon、Christopher Mohr、Douglas A. Whittington、Annette Bak、James Bready、Sean Caenepeel、Angela Coxon、Holly L. Deak、Jenne Fretland、Yan Gu、Brian L. Hodous、Xin Huang、Joseph L. Kim、Jasmine Lin、Alexander M. Long、Hanh Nguyen、Philip R. Olivieri、Vinod F. Patel、Ling Wang、Yihong Zhou、Paul Hughes、Stephanie Geuns-Meyer

  DOI：10.1016/j.bmcl.2008.11.056

  日期：2009.1

  Selective small molecule inhibitors of Tie-2 kinase are important tools for the validation of Tie-2 signaling in pathological angiogenesis. Reported herein is the optimization of a nonselective scaffold into a potent and highly selective inhibitor of Tie-2 kinase.